CATX — Perspective Therapeutics Share News
0.000.00%
Last trade - 00:00- $183.78m
- -$51.49m
- $0.88m
Brief: Perspective Therapeutics Q2 EPS USD -0.22
Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Brief: Perspective Therapeutics FY EPS USD -1.4
Perspective Therapeutics jumps after $175 mln equity offering
Perspective Therapeutics Q3 net loss widens to $26 mln
Brief: Perspective Therapeutics Q3 EPS USD -0.35
Brief: Perspective Therapeutics Appoints Biotech Veteran Joel Sendek As Chief Financial Officer
Brief: Perspective Therapeutics Appoints Biotech Veteran Joel Sendek As Chief Financial Officer
Brief: Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
Brief: Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma
U.S. RESEARCH ROUNDUP-Apple, Tesla, Walmart
U.S. RESEARCH ROUNDUP- Advanced Micro Devices, Carmax, Lockheed Martin
Brief: Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026
Brief: Perspective Therapeutics Announces First Patient Dosed With VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma
Brief: Perspective Therapeutics Provides Business Updates And Strategic Priorities Ahead Of Presentation At 43Rd Annual J.P. Morgan Healthcare Conference
Brief: Perspective Therapeutics Appoints Juan Graham As CFO